EPAS1

Across TCGA pan-cancer cohorts, EPAS1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EPAS1 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher EPAS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EPAS1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LIHC show a favorable association.

THYM, SKCM, and SARC are the cancer types where EPAS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	II,III,IV	0.169	0.905	<.001	27	view →
SKCM	OS	Median	All	0.230	0.781	.004	15	view →
SARC	DFS	Median	All	0.096	0.611	.005	6	view →
BLCA	OS	Median	III,IV	0.149	0.581	.020	6	view →
UCEC	DFS	Median	All	0.869	0.614	.034	2	view →
LIHC	DFS	Median	II,III,IV	1.000	0.191	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EPAS1–THYM (OS)

Open the THYM breakdown →